Mesoblast Limited (MESO) fair value analysis
Nasdaq · Updated 2026-09-07
Mesoblast Limited is a biotechnology company that develops cell-based medicines and regenerative medicine therapies for various diseases and conditions. The company operates globally with research and development activities based in Australia and the United States.
Valuation status
Awaiting full valuationMESO does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $14.47
- Sector
- Healthcare
- 12-month range
- $14.09–$18.16
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Downtrend
- 52-week position
- The bottom quarter of its range
What our data shows for MESO
- Shares are trading in the lower third of their 12-month price range of $14.09–$18.16.
- The 14-day relative strength index sits at a neutral 60.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for MESO
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent MESO news
TickrTrends' derived news-sentiment signal for MESO is currently leaning positive, computed from recent coverage.
- Mesoblast Limited (MESO) Q4 2026 Earnings Call Transcript (seekingalpha.com, 2026-08-27)
TickrTrends take: Mesoblast Limited's Q4 2026 earnings call provides an opportunity to assess the company's operational progress and financial performance at a time when TickrTrends' valuation analysis remains incomplete. For investors focused on valuation metrics, the earnings transcript should be examined for updates on revenue trends, pipeline advancement, cash position, and near-term catalysts that could inform a fuller valuation framework. Given the Healthcare sector's sensitivity to clinical progress and regulatory developments, the call's discussion of product commercialization status and R&D efficiency may be particularly relevant to establishing a more complete valuation picture. - Full Year 2026 Mesoblast Limited Earnings Presentation Transcript (gurufocus.com, 2026-08-27)
TickrTrends take: Mesoblast Limited released its full year 2026 earnings presentation, providing updated financial and operational results for investors analyzing the company's fundamental performance. TickrTrends is currently awaiting a full valuation assessment for the healthcare company, meaning investors should monitor the earnings data presented for key metrics that will inform the company's valuation positioning. As Mesoblast operates in the competitive healthcare sector, its earnings trajectory and operational progress will be critical factors in determining its appropriate valuation relative to peers and market conditions. - Mesoblast Reports Substantial Revenue Growth to US$120M (manilatimes.net, 2026-08-27)
TickrTrends take: Mesoblast's achievement of US$120M in revenue represents a significant milestone for the Healthcare sector company as it transitions toward profitability and cash generation. With TickrTrends currently awaiting full valuation on the stock, investors focused on valuation metrics should monitor whether this revenue growth translates into expanding margins and positive cash flow, as these factors will be critical to establishing an appropriate valuation multiple. The company's ability to sustain and accelerate this revenue trajectory will be essential context for any future valuation assessment.
What people are saying
Follow the MESO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is MESO stock undervalued?
MESO does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is MESO's TickrTrends verdict?
MESO is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is MESO overbought or oversold?
MESO's 14-day RSI is in neutral territory - neither overbought nor oversold.